PDCD1 and cancer: Indeed, cancer immunotherapies aiming at Tex cell reinvigoration, such as monoclonal antibodies targeting PD-1, PD-L1, or CTLA-4, namely checkpoint inhibitors, alone or in combination with CAR-Ts, marked a breakthrough in cancer immunotherapy.